Genetic variants in peroxisome proliferator-activated receptor-γ gene are associated with risk of lung cancer in a Chinese population

Carcinogenesis

Volumn 29, Issue 2, 2008, Pages 342-350

  Chen, Dan ^a   Jin, Guangfu ^b   Wang, Ying ^c   Wang, Haifeng ^c   Liu, Hongliang ^a   Liu, Yanhong ^a   Fan, Weiwei ^a   Ma, Hongxia ^b   Miao, Ruifeng ^b   Hu, Zhibin ^b   Sun, Weiwei ^c   Qian, Ji ^a   Jin, Li ^a,c   Wei, Qingyi ^d   Shen, Hongbing ^b   Huang, Wei ^c   Lu, Daru ^a  

^a FUDAN UNIVERSITY   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

^c CHINESE NATIONAL HUMAN GENOME CENTER AT SHANGHAI   (China)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENINE; GUANINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ARTICLE; CANCER INCIDENCE; CANCER RISK; CHINESE; CIGARETTE SMOKING; CONTROLLED STUDY; GENE INTERACTION; GENE LOCUS; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; HAPLOTYPE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LUNG CANCER; MAJOR CLINICAL STUDY; NUCLEOTIDE SEQUENCE; POPULATION BASED CASE CONTROL STUDY; POPULATION GENETICS; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM;

CASE-CONTROL STUDIES; CHINA; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HAPLOTYPES; HUMANS; LUNG NEOPLASMS; MALE; MODELS, STATISTICAL; ODDS RATIO; POLYMORPHISM, SINGLE NUCLEOTIDE; PPAR GAMMA; RISK; SMOKING; VARIATION (GENETICS);

EID: 40549144850     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgm285     Document Type: Article

References (49)

1. Parkin,D.M. et al. (2005) Global cancer statistics, 2002. CA Cancer J. Clin., 55, 74-108.
2. American Cancer Society, I. (2003). Cancer facts and figures 2003. American Cancer Society, Atlanta, GA.
3. Tsou,J.A. et al. (2002) DNA methylation analysis: A powerful new tool for lung cancer diagnosis. Oncogene, 21, 5450-5461.
4. Nadel,J.A. (2001) Role of epidermal growth factor receptor activation in regulating mucin synthesis. Respir Res., 2, 85-89.
5. Adler,K.B. et al. (1994) Interactions between respiratory epithelial cells and cytokines: Relationships to lung inflammation. Ann. Ny Acad. Sci., 725, 128-145.
6. Takeyama,K. et al. (2001) Activation of epidermal growth factor receptors is responsible for mucin synthesis induced by cigarette smoke. Am. J. Physiol. Lung Cell. Mol. Physiol., 280, L165-L172.
7. Jones,R. et al. (1973) Goblet cell glycoprotein and tracheal gland hypertrophy in rat airways: The effect of tobacco smoke with or without the anti-inflammatory agent phenylmethyloxadiazole. Br J. Exp. Plathol., 54, 229-239.
8. Balkwill,F. et al. (2001) Inflammation and cancer: Back to Virchow? Lancet, 357, 539-545.
9. Fitzpatrick,F.A. (2001) Inflammation, carcinogenesis and cancer. Int. Immunopharmacol., 1, 1651-1667.
10. Godschalk,R. et al. (2002) Comparison of multiple DNA adduct types in tumor adjacent human lung tissue: Effect of cigarette smoking. Carcinogenesis, 23, 2081-2086.
11. Ames,B.N. et al. (1995) The causes and prevention of cancer. Proc. Natl Acad. Sci. USA, 92, 5258-5265.
12. Boffett,P. et al. (2002) Lung cancer risk in a population-based cohort of patients hospitalized for asthma in Sweden. Eur. Respir. J. 19, 127-133.
13. Sasco,A.J. et al. (2002) A case-control study of lung cancer in Casablanca, Morocco. Cancer Causes Control, 13, 609-616.
14. Cohen,B.H. et al. (1977) A common familial component in lung cancer and chronic obstructive pulmonary disease. Lancet, 2, 523-526.
15. Standiford,T.J. et al. (2005) Peroxisome proliferator-activated receptor-{gamma} as a regulator of lung inflammation and repair. Proc. Am. Thorac. Soc., 2, 226-231.
16. Kota,B.P. et al. (2005) An overview on biological mechanisms of PPARs. Pharmacol. Res., 51, 85-94.
17. Debril,M.B. et al. (2001) The pleiotropic functions of peroxisome proliferator-activated receptor gamma. J. Mol. Med., 79, 30-47.
18. Kersten,S. et al. (2000) Roles of PPARs in health and disease. Nature, 405, 421-424.
19. Keshamouni,V.G. et al. (2004) Peroxisome proliferator-activated receptor-gamma activation inhibits tumor progression in non-small-cell lung cancer. Oncogene, 23, 100-108.
20. Inoue,K. et al. (2001) Expression of peroxisome proliferator-activated receptor (PPAR)-gamma in human lung cancer. Anticancer Res., 21, 2471-2476.
21. Tsubouchi,Y. et al. (2000) Inhibition of human lung cancer cell growth by the peroxisome proliferator-activated receptor-gamma agonists through induction of apoptosis. Biochem. Biophys. Res. Commun., 270, 400-405.
22. Li,M. et al. (2005) Activation of peroxisome proliferator-activated receptor-gamma by troglitazone (TGZ) inhibits human lung cell growth. J. Cell. Biochem., 96, 760-774.
23. Bren-Mattison,Y. et al. (2005) Peroxisome proliferator-activated receptor-gamma (PPAR(gamma)) inhibits tumorigenesis by reversing the undifferentiated phenotype of metastatic non-small-cell lung cancer cells (NSCLC). Oncogene, 24, 1412-1422.
24. Han,S. et al. (2004) Suppression of prostaglandin E2 receptor subtype EP2 by PPARgamma ligands inhibits human lung carcinoma cell growth. Biochem. Biophys. Res. Commun., 314, 1093-1099.
25. Satoh,T. et al. (2002) Activation of peroxisome proliferator-activated receptor-gamma stimulates the growth arrest and DNA-damage inducible 153 gene in non-small cell lung carcinoma cells. Oncogene, 21, 2171-2180.
26. Hu,Z. et al. (2007) Genetic variants in MGMT and risk of lung cancer in Southeastern Chinese: A haplotype-based analysis. Hum. Mutat., 28, 431-440.
27. Fajas,L. et al. (1997) The organization, promoter analysis, and expression of the human PPARgamma gene. J. Biol. Chem., 272, 18779-18789.
28. Fajas,L. et al. (1998) PPARgamma3 mRNA: A distinct PPARgamma mRNA subtype transcribed from an independent promoter. FEBS Lett., 438, 55-60.
29. Akaike,H. (1974) A new look at the statistical model identification. IEEE Trans. Automat. Contr, 19, 716-723.
30. Lewontin,R.C. (1988) On measures of gametic disequilibrium. Genetics 120, 849-852.
31. Gabriel,S.B. et al. (2002) The structure of haplotype blocks in the human genome. Science, 296, 2225-2229.
32. Stephens,M. et al. (2003) A comparison of Bayesian methods for haplotype reconstruction from population genotype data. Am. J. Hum. Genet., 73, 1162-1169.
33. Abbott,W. et al. (2007) Polymorphism in intron 1 of the interferon-gamma gene influences both serum immunoglobulin E levels and the risk for chronic hepatitis B virus infection in Polynesians. Immunogenetics, 59, 187-195.
34. Zhou,L. et al. (2006) Intron 1 sequences are required for pancreatic expression of the human proglucagon gene. Am. J. Physiol. Regal. Integr. Comp. Physiol., 290, R634-R641.
35. Kawada,N. et al. (1999) Role of intron 1 in smooth muscle alpha-actin transcriptional regulation in activated mesangial cells in vivo. Kidney Int., 55, 2338-2348.
36. Estany,J. et al. (2007) Association of a CA repeat polymorphism at intron 1 of the IGF1 gene with circulating insulin-like growth factor 1 concentration, growth and fatness in swine. Physiol. Genomics, 31, 236-243.
37. Sasaki,H. et al. (2002) Decreased perioxisome proliferator-activated receptor gamma gene expression was correlated with poor prognosis in patients with lung cancer. Lung Cancer, 36, 71-76.
38. Meirhaeghe,A. et al. (2003) A functional polymorphism in a STAT5B. site of the human PPARγ3 gene promoter affects height and lipid metabolism in a French population. Arterioscler. Thromb. Vasc. Biol. 23, 289-294.
39. Stumvoll,M. et al. (2002) The peroxisome proliferator-activated receptor-gamma2 Pro12Ala polymorphism. Diabetes, 51, 2341-2347.
40. Huang,J.T. et al. (1999) Interleukin-4-dependent production of PPAR-gamma ligands in macrophages by 12/15-lipoxygenase. Nature, 400, 378-382.
41. Wang,A.C. et al. (2001) Peroxisome proliferator-activated receptor-gamma regulates airway epithelial cell activation. Am. J. Respir. Cell Mol Biol., 24, 683-693.
42. Ma,H. et al. (2007) Tagging single nucleotide polymorphisms in excision repair cross-complementing group 1 (ERCC1) and risk of primary lung cancer in a Chinese population. Pharmacogenet. Genomics, 17, 417-423.
43. Ohashi,J. et al. (2001) The power of genome-wide association studies of complex disease genes: Statistical limitations of indirect approaches using SNP markers. J. Hum. Genet., 46, 478-482.
44. Pritchard,J.K. et al. (2002) The allelic architecture of human disease genes: Common disease-common variant...or not? Hum. Mol. Genet., 11, 2417-2423.
45. Nyholt,D.R. (2004) A simple correction for multiple testing for single-nucleotide polymorphisms in linkage disequilibrium with each other. Am. J. Hum. Genet., 74, 765-769.
46. Churchil,G.A. et al. (1994) Empirical threshold values for quantitative trait mapping. Genetics, 138, 963-971.
47. Dudbridge,F. et al. (2006) Detecting multiple associations in genome-wide studies. Hum. Genomics., 2, 310-317.
48. Dudbridge,F. et al. (2004) Efficient computation of significance levels for multiple associations in large studies of correlated data, including genomewide association studies. Am. J. Hum. Genet., 75, 424-435.
49. Dudbridge,F. (2006) A note on permutation tests in multistage association scans. Am. J. Hum. Genet., 78, 1094-1095.